GSK shares rise after £1.7bn Zantac settlement pharma GSK shares have spiked today after the pharmaceutical giant agreed to pay as much as $2.2bn (£1.68bn) to settle lawsuits alleging one of its heartburn drugs had caused cancer. The discontinued version of the drug, Zantac, had triggered 80,000 lawsuits from 10 different law firms in the US and has hung over the FTSE 100 [...]
Pharma giants GSK, Pfizer and Sanofi granted supreme court hearing in Zantac cancer lawsuits pharma Delaware’s top court is set to hear an appeal from GSK and other pharmaceutical giants to throw out over 70,000 lawsuits alleging that the now-discontinued heartburn drug Zantac caused cancer. The companies, which also include Pfizer and Sanofi, are challenging a lower court ruling that allowed expert testimony claiming Zantac causes cancer – a link [...]
GSK wins latest Zantac trial as jury finds drug did not cause woman’s cancer pharma GSK - formerly GlaxoSmithKline - has won its latest trial over whether its most popular drug caused cancer on Monday, after a jury found it was not the root cause of an American woman's illness.
US drug giant Pfizer beats GSK to UK government contract for 4.9m vaccine shots June 25, 2024 Pfizer has beaten GSK to win a contract to supply millions of doses of a new respiratory vaccine in the UK after the government snubbed the local drugmaker.
GSK shares drag the FTSE 100 as company faces muli-billion pound bill after Zantac trial ruling June 3, 2024 GSK has hit back against a US ruling that found it could be sued over the potential cancer-causing properties of its heartburn drug Zantac.
GSK: How much could the Zantac lawsuits cost? June 3, 2024 Last month, Shore Capital analysts estimated that up to $30bn (£24bn) for litigation was already priced into GSK’s shares.
Polar Capital Healthcare trust rockets to success thanks to strong stock selection May 16, 2024 The trust performed much better than the previous year, where it grew only 4.2 per cent, thanks to strong stock selection and managing to outperform an already booming healthcare market.